Glioblastoma.
Wirsching HG, Galanis E, Weller M.
Handb Clin Neurol. 2016;134:381-97. doi: 10.1016/B978-0-12-802997-8.00023-2.
Molecular targeted therapy of glioblastoma.
Le Rhun E, Preusser M, Roth P, Reardon DA, van den Bent M, Wen P, Reifenberger G, Weller M.
Cancer Treat Rev. 2019 Nov;80:101896. doi: 10.1016/j.ctrv.2019.101896. Epub 2019 Sep 11.
Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer.
Gimple RC, Bhargava S, Dixit D, Rich JN.
Genes Dev. 2019 Jun 1;33(11-12):591-609. doi: 10.1101/gad.324301.119.
Glioblastoma and other malignant gliomas: a clinical review.
Omuro A, DeAngelis LM.
JAMA. 2013 Nov 6;310(17):1842-50. doi: 10.1001/jama.2013.280319.
A comprehensive profile of recurrent glioblastoma.
Campos B, Olsen LR, Urup T, Poulsen HS.
Oncogene. 2016 Nov 10;35(45):5819-5825. doi: 10.1038/onc.2016.85. Epub 2016 Apr 4.
Glioblastoma and brain connectivity: the need for a paradigm shift.
Salvalaggio A, Pini L, Bertoldo A, Corbetta M.
Lancet Neurol. 2024 Jul;23(7):740-748. doi: 10.1016/S1474-4422(24)00160-1.
The definition of primary and secondary glioblastoma.
Ohgaki H, Kleihues P.
Clin Cancer Res. 2013 Feb 15;19(4):764-72. doi: 10.1158/1078-0432.CCR-12-3002. Epub 2012 Dec 3.
Single-cell characterization of macrophages in glioblastoma reveals MARCO as a mesenchymal pro-tumor marker.
Chen AX, Gartrell RD, Zhao J, Upadhyayula PS, Zhao W, Yuan J, Minns HE, Dovas A, Bruce JN, Lasorella A, Iavarone A, Canoll P, Sims PA, Rabadan R.
Genome Med. 2021 May 19;13(1):88. doi: 10.1186/s13073-021-00906-x.
[Glioblastoma in 2017].
Duffau H.
Rev Infirm. 2017 Feb;66(228):16-18. doi: 10.1016/j.revinf.2016.12.002.
Identification of hypoxic macrophages in glioblastoma: Unveiling therapeutic insights from tumour microenvironment analysis.
Qin Z, Bian XW, Shi Y.
Clin Transl Med. 2024 Sep;14(9):e70013. doi: 10.1002/ctm2.70013.
